Építés alatt – nem éles oldal
Belépés
Befejeződött4. fázis

Postinfectious Irritable Bowel Syndrome and Gelsectan

A legfontosabb adatok

Ki végzi
Evangelismos Hospital
Hol
Görögország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
4. fázis
Résztvevők
275 fő vett részt
Kezdés
2021. szept. 1.
Befejezés
2024. febr. 26.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • (Gelsectan, Devintec Sagl)
A regiszteradat frissítve
2024. február 28.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 14 feltétel megnézéseKevesebb

Ki vehet részt

  • Patients with diarrhea-predominant post-infectious IBSand patients with diarrhea predominant classical IBS (non PI-IBS) who will be used as controls
  • Diagnosis of IBS will be made according to the ROME iV criteria as following:
  • Recurrent abdominal pain, on average, at least 1 day/week in the last 3 months, associated with two or more of the following criteria:
  • Related to defecation
  • Associated with a change in frequency of stool
  • Associated with a change in form (appearance) of stool. The above-mentioned criteria have to be fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis; Diagnosis of post infectious IBS will be made according to the Rome Foundation Working Team criteria as following:; Recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, with symptom onset at least 6 months before diagnosis, associated with two of the following:
  • defecation
  • a change in frequency of stool
  • a change in form (appearance) of stool Symptom development immediately after resolution of acute infectious gastroenteritis; Infectious gastroenteritis should be defined by positive stool culture in a symptomatic individual or presence of two of the following acute symptoms (when stool culture not available):
  • fever
  • vomiting
  • diarrhea

Ki nem vehet részt

  • Patients should not meet criteria for IBS before onset of acute illness
  • We will exclude patients who are pregnant, who have an oncology history (since these patients might exhibit diarrhea due to their underlying illness) and patients with alcohol dependence (due to the non-compliance shown by these patients) and patients with known hypersensitivity or allergy to any of the ingredients included in Gelsectan

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

Irritable Bowel Syndrome (IBS) is one of the most common conditions diagnosed in gastroenterology practice. Acute infectious gastroenteritis represents the strongest known risk factor for IBS development; a condition known as post-infection IBS (PI-IBS). PI-IBS patients are more likely than sporadic IBS patients to exhibit a diarrhea-predominant phenotype. The investigators plan to prospectively recruit two groups of patients: patients with diarrhea-predominant post-infectious IBSand patients with diarrhea predominant classical IBS (non PI-IBS) who will be used as controls.

A teljes eredeti leírásKevesebb

Patients included in the study will receive for 28 days a capsule containing Tamarind seed polysaccharide containing xyloglucan, combined with a pea protein reticulated with grape seed extractand a prebiotic, the xilooligosaccharide (Gelsectan, Devintec Sagl) twice daily.

A vizsgálat csoportja

  • Postinfectious ibs and diarrhea predominant classical IBSA vizsgált kezelés

    Capsule containing Tamarind seed polysaccharide containing xyloglucan, combined with a pea protein reticulated with grape seed extractand a prebiotic, the xilooligosaccharide (Gelsectan, Devintec sagl) twice daily

    Kezelés: (Gelsectan, Devintec Sagl)

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Treatment of Postinfectious Irritable Bowel Syndrome and Noninfective Irritable Bowel Syndrome With Gelsectan
A regiszteradat frissítve
2024. február 28.